Medications

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

Q&A: When will patients see personalized cancer vaccines?

Catherine Wu has been a pioneer in a promising approach to fight cancer: vaccines that target specific immune-stimulating molecules, known as immunogenic peptides, generated by the distinct genetic mutations of any individual ...

page 10 from 29